Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC1011 tablets in idiopathic pulmonary fibrosis (IPF) – randomized double-blind placebo-controlled phase II/III trial
CTR20230327Phase 2Active
- Sponsor
- Zhikang Biopharma
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing SC1011 active arm with SC1011 placebo arm (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity (FVC). Started Jun 2023; status: active.
02
Drugs
sufenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20230327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230327.